Velufenacin

A medication used to treat overactive bladder

Velufenacin
File:Velufenacin.svg
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Velufenacin is a medication used in the management of overactive bladder (OAB) with symptoms of urinary incontinence, urinary urgency, and urinary frequency. It is classified as a muscarinic antagonist, which works by relaxing the bladder muscles to prevent urgent, frequent, or uncontrolled urination.

Mechanism of Action

Velufenacin functions as a selective antagonist of the M3 muscarinic receptor subtype. The M3 receptors are primarily responsible for mediating bladder muscle contractions. By inhibiting these receptors, Velufenacin reduces the involuntary contractions of the bladder, thereby alleviating the symptoms of overactive bladder.

Pharmacokinetics

Velufenacin is administered orally and is well absorbed from the gastrointestinal tract. It undergoes extensive hepatic metabolism, primarily via the cytochrome P450 enzyme system. The drug and its metabolites are excreted mainly in the urine.

Clinical Use

Velufenacin is indicated for the treatment of overactive bladder in adults. It is particularly useful in patients who experience significant urinary incontinence and urgency. The typical dosage regimen involves once-daily administration, which helps improve patient compliance.

Side Effects

Common side effects of Velufenacin include dry mouth, constipation, and blurred vision. These effects are related to its anticholinergic properties. Less common but more serious side effects can include urinary retention and tachycardia.

Contraindications

Velufenacin is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. Caution is advised in patients with hepatic impairment or renal impairment.

Related pages

• Overactive bladder
• Muscarinic antagonist
• Urinary incontinence